Furthermore, intermediate IL8 expression levels were observed in a group with limited sensitivity to cetuximab, with tumour volume changes between 35% increase and 50% reduction, which is considered as stable disease (SD) (Figure 6A, B). The gene discussed is CXCL8; the disease is neoplasm.